Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma

Anna Russignan, Cecilia Spina, Nicola Tamassia, Adriana Cassaro, Antonella Rigo, Anna Bagnato, Laura Rosanò, Angela Bonalumi, Michele Gottardi, Lucia Zanatta, Alice Giacomazzi, Maria Teresa Scupoli, Martina Tinelli, Ugo Salvadori, Federico Mosna, Alberto Zamò, Marco A Cassatella, Fabrizio Vinante, Cristina Tecchio

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis, consisting of EDN1 acting through EDN-receptor A (EDNRA) and B (EDNRB), was previously shown to be overexpressed in several tumours, including MM. However, there is incomplete understanding of how EDN1 axis regulates MM growth and response to therapy. Besides EDNRA, the majority of MM cell lines and primary malignant PCs express high levels of EDNRB and release EDN1. Similarly, bone-marrow microenvironment cells also secrete EDN1. Investigating the extent of epigenetic dysregulation of EDNRB gene in MM, we found that hypermethylation of EDNRB promoter and subsequent down-regulation of EDNRB gene was observed in PCs or B lymphocytes from healthy donors compared to EDNRB-expressing malignant PCs. Pharmacological blockade with the dual EDN1 receptor antagonist bosentan decreased cell viability and MAPK activation of U266 and RPMI-8226 cells. Interestingly, the combination of bosentan and the proteasome inhibitor bortezomib, currently approved for MM treatment, resulted in synergistic cytotoxic effects. Overall, our data has uncovered EDN1-mediated autocrine and paracrine mechanisms that regulate malignant PCs growth and drug response, and support EDN1 receptors as new therapeutic targets in MM.

Original languageEnglish
Pages (from-to)781-793
Number of pages13
JournalBritish Journal of Haematology
Volume178
Issue number5
DOIs
Publication statusPublished - Sep 2017

Fingerprint

Endothelin A Receptors
Multiple Myeloma
Endothelin-1
Plasma Cells
Therapeutics
Proteasome Inhibitors
Growth
Epigenomics
Bone Marrow Cells
Genes
Cell Survival
B-Lymphocytes
Down-Regulation
Tissue Donors
Pharmacology
Cell Line
Pharmaceutical Preparations

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Autocrine Communication
  • Bortezomib
  • Cell Proliferation
  • Cell Survival
  • DNA Methylation
  • DNA, Neoplasm
  • Drug Synergism
  • Endothelin A Receptor Antagonists
  • Endothelin-1
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Multiple Myeloma
  • Plasma Cells
  • Promoter Regions, Genetic
  • Receptor, Endothelin A
  • Sulfonamides
  • Tumor Cells, Cultured
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. / Russignan, Anna; Spina, Cecilia; Tamassia, Nicola; Cassaro, Adriana; Rigo, Antonella; Bagnato, Anna; Rosanò, Laura; Bonalumi, Angela; Gottardi, Michele; Zanatta, Lucia; Giacomazzi, Alice; Scupoli, Maria Teresa; Tinelli, Martina; Salvadori, Ugo; Mosna, Federico; Zamò, Alberto; Cassatella, Marco A; Vinante, Fabrizio; Tecchio, Cristina.

In: British Journal of Haematology, Vol. 178, No. 5, 09.2017, p. 781-793.

Research output: Contribution to journalArticle

Russignan, A, Spina, C, Tamassia, N, Cassaro, A, Rigo, A, Bagnato, A, Rosanò, L, Bonalumi, A, Gottardi, M, Zanatta, L, Giacomazzi, A, Scupoli, MT, Tinelli, M, Salvadori, U, Mosna, F, Zamò, A, Cassatella, MA, Vinante, F & Tecchio, C 2017, 'Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma', British Journal of Haematology, vol. 178, no. 5, pp. 781-793. https://doi.org/10.1111/bjh.14771
Russignan, Anna ; Spina, Cecilia ; Tamassia, Nicola ; Cassaro, Adriana ; Rigo, Antonella ; Bagnato, Anna ; Rosanò, Laura ; Bonalumi, Angela ; Gottardi, Michele ; Zanatta, Lucia ; Giacomazzi, Alice ; Scupoli, Maria Teresa ; Tinelli, Martina ; Salvadori, Ugo ; Mosna, Federico ; Zamò, Alberto ; Cassatella, Marco A ; Vinante, Fabrizio ; Tecchio, Cristina. / Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. In: British Journal of Haematology. 2017 ; Vol. 178, No. 5. pp. 781-793.
@article{77c5066ad9bd4292b43913b87a88bb11,
title = "Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma",
abstract = "New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis, consisting of EDN1 acting through EDN-receptor A (EDNRA) and B (EDNRB), was previously shown to be overexpressed in several tumours, including MM. However, there is incomplete understanding of how EDN1 axis regulates MM growth and response to therapy. Besides EDNRA, the majority of MM cell lines and primary malignant PCs express high levels of EDNRB and release EDN1. Similarly, bone-marrow microenvironment cells also secrete EDN1. Investigating the extent of epigenetic dysregulation of EDNRB gene in MM, we found that hypermethylation of EDNRB promoter and subsequent down-regulation of EDNRB gene was observed in PCs or B lymphocytes from healthy donors compared to EDNRB-expressing malignant PCs. Pharmacological blockade with the dual EDN1 receptor antagonist bosentan decreased cell viability and MAPK activation of U266 and RPMI-8226 cells. Interestingly, the combination of bosentan and the proteasome inhibitor bortezomib, currently approved for MM treatment, resulted in synergistic cytotoxic effects. Overall, our data has uncovered EDN1-mediated autocrine and paracrine mechanisms that regulate malignant PCs growth and drug response, and support EDN1 receptors as new therapeutic targets in MM.",
keywords = "Adult, Aged, Aged, 80 and over, Autocrine Communication, Bortezomib, Cell Proliferation, Cell Survival, DNA Methylation, DNA, Neoplasm, Drug Synergism, Endothelin A Receptor Antagonists, Endothelin-1, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Molecular Targeted Therapy, Multiple Myeloma, Plasma Cells, Promoter Regions, Genetic, Receptor, Endothelin A, Sulfonamides, Tumor Cells, Cultured, Journal Article, Research Support, Non-U.S. Gov't",
author = "Anna Russignan and Cecilia Spina and Nicola Tamassia and Adriana Cassaro and Antonella Rigo and Anna Bagnato and Laura Rosan{\`o} and Angela Bonalumi and Michele Gottardi and Lucia Zanatta and Alice Giacomazzi and Scupoli, {Maria Teresa} and Martina Tinelli and Ugo Salvadori and Federico Mosna and Alberto Zam{\`o} and Cassatella, {Marco A} and Fabrizio Vinante and Cristina Tecchio",
note = "{\circledC} 2017 John Wiley & Sons Ltd.",
year = "2017",
month = "9",
doi = "10.1111/bjh.14771",
language = "English",
volume = "178",
pages = "781--793",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma

AU - Russignan, Anna

AU - Spina, Cecilia

AU - Tamassia, Nicola

AU - Cassaro, Adriana

AU - Rigo, Antonella

AU - Bagnato, Anna

AU - Rosanò, Laura

AU - Bonalumi, Angela

AU - Gottardi, Michele

AU - Zanatta, Lucia

AU - Giacomazzi, Alice

AU - Scupoli, Maria Teresa

AU - Tinelli, Martina

AU - Salvadori, Ugo

AU - Mosna, Federico

AU - Zamò, Alberto

AU - Cassatella, Marco A

AU - Vinante, Fabrizio

AU - Tecchio, Cristina

N1 - © 2017 John Wiley & Sons Ltd.

PY - 2017/9

Y1 - 2017/9

N2 - New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis, consisting of EDN1 acting through EDN-receptor A (EDNRA) and B (EDNRB), was previously shown to be overexpressed in several tumours, including MM. However, there is incomplete understanding of how EDN1 axis regulates MM growth and response to therapy. Besides EDNRA, the majority of MM cell lines and primary malignant PCs express high levels of EDNRB and release EDN1. Similarly, bone-marrow microenvironment cells also secrete EDN1. Investigating the extent of epigenetic dysregulation of EDNRB gene in MM, we found that hypermethylation of EDNRB promoter and subsequent down-regulation of EDNRB gene was observed in PCs or B lymphocytes from healthy donors compared to EDNRB-expressing malignant PCs. Pharmacological blockade with the dual EDN1 receptor antagonist bosentan decreased cell viability and MAPK activation of U266 and RPMI-8226 cells. Interestingly, the combination of bosentan and the proteasome inhibitor bortezomib, currently approved for MM treatment, resulted in synergistic cytotoxic effects. Overall, our data has uncovered EDN1-mediated autocrine and paracrine mechanisms that regulate malignant PCs growth and drug response, and support EDN1 receptors as new therapeutic targets in MM.

AB - New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin-1 (EDN1) axis, consisting of EDN1 acting through EDN-receptor A (EDNRA) and B (EDNRB), was previously shown to be overexpressed in several tumours, including MM. However, there is incomplete understanding of how EDN1 axis regulates MM growth and response to therapy. Besides EDNRA, the majority of MM cell lines and primary malignant PCs express high levels of EDNRB and release EDN1. Similarly, bone-marrow microenvironment cells also secrete EDN1. Investigating the extent of epigenetic dysregulation of EDNRB gene in MM, we found that hypermethylation of EDNRB promoter and subsequent down-regulation of EDNRB gene was observed in PCs or B lymphocytes from healthy donors compared to EDNRB-expressing malignant PCs. Pharmacological blockade with the dual EDN1 receptor antagonist bosentan decreased cell viability and MAPK activation of U266 and RPMI-8226 cells. Interestingly, the combination of bosentan and the proteasome inhibitor bortezomib, currently approved for MM treatment, resulted in synergistic cytotoxic effects. Overall, our data has uncovered EDN1-mediated autocrine and paracrine mechanisms that regulate malignant PCs growth and drug response, and support EDN1 receptors as new therapeutic targets in MM.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Autocrine Communication

KW - Bortezomib

KW - Cell Proliferation

KW - Cell Survival

KW - DNA Methylation

KW - DNA, Neoplasm

KW - Drug Synergism

KW - Endothelin A Receptor Antagonists

KW - Endothelin-1

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Male

KW - Middle Aged

KW - Molecular Targeted Therapy

KW - Multiple Myeloma

KW - Plasma Cells

KW - Promoter Regions, Genetic

KW - Receptor, Endothelin A

KW - Sulfonamides

KW - Tumor Cells, Cultured

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/bjh.14771

DO - 10.1111/bjh.14771

M3 - Article

VL - 178

SP - 781

EP - 793

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -